keyword
MENU ▼
Read by QxMD icon Read
search

Trastuzumab cardiotoxicity

keyword
https://www.readbyqxmd.com/read/28066861/the-incidence-of-cardiomyopathy-in-brca1-and-brca2-mutation-carriers-after-anthracycline-based-adjuvant-chemotherapy
#1
Edward J Pearson, Anju Nair, Yahya Daoud, Joanne L Blum
PURPOSE: Breast cancer remains the fourth-leading cause of death in the United States. Nearly 10% of breast cancers are hereditary, with deleterious mutations in BRCA1 and BRCA2 genes being the leading cause. Anthracycline chemotherapy, used commonly for breast cancer, carries cardiotoxicity risk. Recent studies demonstrated anthracycline-induced cardiac failure in homozygous BRCA2-deficient mice and increased rates of heart failure in homozygous BRCA1-deficient mice following ischemic insult...
January 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28059036/reduction-of-doxorubicin-induced-cardiotoxicity-using-nanocarriers-a-review
#2
Michaela Fojtu, Jaromir Gumulec, Tibor Stracina, Martina Raudenska, Anna Skotakova, Marketa Vaculovicova, Vojtech Adam, Petr Babula, Marie Novakova, Michal Masarik
BACKGROUND: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors...
January 5, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/28053628/chemotherapy-induced-left-ventricular-dysfunction-in-patients-with-breast-cancer
#3
Hyun Ju Yoon, Kye Hun Kim, Jong Yoon Kim, Hyuk Jin Park, Jae Yeong Cho, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park
PURPOSE: As the numbers of cancer cases and survivors increase, the incidence and natural history of chemotherapy-induced cardiotoxicities in patients with breast cancer may also be expected to change. The present study aimed to investigate the incidence and predictors of chemotherapy-induced left ventricular dysfunction (LVD) in patients with breast cancer. METHODS: From 2003 to 2010, 712 female patients with breast cancer (55.7±10.7 years) were enrolled and divided into the LVD group (n=82, 56...
December 2016: Journal of Breast Cancer
https://www.readbyqxmd.com/read/27956153/small-benefits-in-trastuzumab-related-cardiotoxicity
#4
Manjulika Das
No abstract text is available yet for this article.
January 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27955938/global-and-regional-patterns-of-longitudinal-strain-in-screening-for-chemotherapy-induced-cardiotoxicity
#5
Guilherme Portugal, Luísa Moura Branco, Ana Galrinho, Miguel Mota Carmo, Ana Teresa Timóteo, Joana Feliciano, João Abreu, Sónia Duarte Oliveira, Lurdes Batarda, Rui Cruz Ferreira
INTRODUCTION: Serial echocardiographic assessment of left ventricular ejection fraction (LVEF) is the gold standard in screening for chemotherapy-induced cardiotoxicity (CIC). Measurement of myocardial deformation using speckle tracking enables more detailed assessment of myocardial contractility. The aim of this study was to determine the relationship between global and regional longitudinal strain and CIC. METHODS: This was a prospective study of 158 breast cancer patients undergoing chemotherapy with anthracyclines with or without adjuvant trastuzumab who underwent serial monitoring by transthoracic echocardiography with assessment of myocardial deformation...
January 2017: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/27911951/body-surface-area-and-baseline-blood-pressure-predict-subclinical-anthracycline-cardiotoxicity-in-women-treated-for-early-breast-cancer
#6
Paul Kotwinski, Gillian Smith, Jackie Cooper, Julie Sanders, Louise Ma, Albert Teis, David Kotwinski, Michael Mythen, Dudley J Pennell, Alison Jones, Hugh Montgomery
BACKGROUND AND AIMS: Anthracyclines are highly effective chemotherapeutic agents which may cause long-term cardiac damage (chronic anthracycline cardiotoxicity) and heart failure. The pathogenesis of anthracycline cardiotoxicity remains incompletely understood and individual susceptibility difficult to predict. We sought clinical features which might contribute to improved risk assessment. METHODS: Subjects were women with early breast cancer, free of pre-existing cardiac disease...
2016: PloS One
https://www.readbyqxmd.com/read/27893331/multidisciplinary-approach-to-novel-therapies-in-cardio-oncology-research-manticore-101-breast-a-randomized-trial-for-the-prevention-of-trastuzumab-associated-cardiotoxicity
#7
Edith Pituskin, John R Mackey, Sheri Koshman, Davinder Jassal, Marshall Pitz, Mark J Haykowsky, Joseph J Pagano, Kelvin Chow, Richard B Thompson, Larissa J Vos, Sunita Ghosh, Gavin Y Oudit, Justin A Ezekowitz, D Ian Paterson
Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive) breast cancer is dose-independent cardiac dysfunction. Angiotensin-converting enzyme inhibitors and β-blockers are recommended first-line agents for heart failure. We hypothesized that angiotensin-converting enzyme inhibitors and β-blockers could prevent trastuzumab-related cardiotoxicity. Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant therapy...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27886160/left-ventricular-end-diastolic-volume-as-an-early-indicator-of-trastuzumab-related-cardiotoxicity-in-patients-with-her2-positive-breast-cancer-results-from-a-single-center-retrospective-study
#8
Corinna Bergamini, Flavia Torelli, Luca Ghiselli, Andrea Rossi, Laura Trevisani, Giulia Vinco, Stella Truong, Giovanni Benfari, Francesca LA Russa, Giorgio Golia, Annamaria Molino, Corrado Vassanelli
BACKGROUND: Adjuvant Trastuzumab therapy increases survival rates in patients with early HER2 positive breast cancer, although it can be potentially cardiotoxic. Aim of the study was to evaluate the prevalence of left ventricular (LV) systolic dysfunction; and the relationship between the presence of cardiovascular risk factors, cardiac therapy and/or echocardiographic parameters of systolic function at baseline and the development of cardiotoxicity in such patients. METHODS: 227 patients were retrospectively reviewed...
November 25, 2016: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/27883296/adjuvant-trastuzumab-a-10-year-overview-of-its-benefit
#9
Matteo Lambertini, Noam F Pondé, Cinzia Solinas, Evandro de Azambuja
Anti-HER2 targeted therapy is one of the key advances in the treatment of breast cancer that have occurred in the last 20 years. In the adjuvant setting, the use of trastuzumab has led to prolonged and sustained survival benefit with very little toxicity as also confirmed by the 10-year follow-up results from the pivotal trials. Despite the survival improvement, several key issues are not entirely resolved in this field. These issues have led to multiple research efforts in de-escalating or escalating the standard treatment with chemotherapy and 1 year of adjuvant trastuzumab...
January 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/27875516/trastuzumab-associated-cardiac-events-in-the-persephone-trial
#10
Helena M Earl, Anne-Laure Vallier, Janet Dunn, Shrushma Loi, Emma Ogburn, Karen McAdam, Luke Hughes-Davies, Adrian Harnett, Jean Abraham, Andrew Wardley, David A Cameron, David Miles, Ioannis Gounaris, Chris Plummer, Louise Hiller
BACKGROUND: We report cardiac events in the Persephone trial which compares 6-12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer. METHODS: Clinical cardiac events were defined as any of the following: symptoms and/or signs of congestive heart failure (CHF) and new or altered CHF medication. In addition, left ventricular ejection fraction (LVEF) was measured at baseline and then 3 monthly for 12 months. RESULTS: A total of 2500 patients, aged 22-82, were included: 1251 randomised to 12 months and 1249 to 6 months of trastuzumab treatment...
December 6, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27858859/risk-factors-of-trastuzumab-induced-cardiotoxicity-in-breast-cancer-a-meta-analysis
#11
Zeeshan Jawa, Ruth M Perez, Lydia Garlie, Maharaj Singh, Rubina Qamar, Bijoy K Khandheria, Arshad Jahangir, Yang Shi
BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is estimated that 1% to 4% of patients treated with trastuzumab will develop heart failure and ∼10% will experience a reduction in left ventricular ejection fraction (LVEF), the patient risk factors associated with trastuzumab-induced cardiotoxicity (TIC) are unclear...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27843627/twenty-years-of-anti-her2-therapy-associated-cardiotoxicity
#12
REVIEW
Noam F Pondé, Matteo Lambertini, Evandro de Azambuja
Over the past 20 years, the prognosis of HER2-positive breast cancer has been transformed by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab (ie, the first anti-HER2 agent to be developed) cardiotoxicity became a major concern. In the first published phase 3 trial of trastuzumab, 27% of patients receiving anthracyclines and trastuzumab experienced cardiac events and 16% suffered from severe congestive heart failure. In subsequent trials conducted in advanced and early settings, the incidence of cardiac events was reduced through changes in chemotherapy regimens, more strict patient selection and close cardiac assessment...
2016: ESMO Open
https://www.readbyqxmd.com/read/27843329/antineoplastic-related-cardiotoxicity-morphofunctional-aspects-in-a-murine-model-contribution-of-the-new-tool-2d-speckle-tracking
#13
Carmela Coppola, Gennaro Riccio, Antonio Barbieri, Maria Gaia Monti, Giovanna Piscopo, Domenica Rea, Claudio Arra, Carlo Maurea, Claudia De Lorenzo, Nicola Maurea
OBJECTIVE: Considering that global left ventricular systolic radial strain is a sensitive technique for the early detection of left ventricular dysfunction due to antineoplastics and the analysis of segmental myocardial contractility, we evaluated this technique for early detection of trastuzumab-related cardiotoxicity by comparing it with cardiac structural damage. METHODS: Groups of six mice were injected with trastuzumab or doxorubicin, used either as single agents or in combination...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27787557/potential-benefit-of-low-dose-candesartan-in-trastuzumab-induced-cardiotoxic-effects
#14
Seongseok Yun, Rostam Khoubyari, Ivo Abraham
No abstract text is available yet for this article.
October 27, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27787551/potential-benefit-of-low-dose-candesartan-in-trastuzumab-induced-cardiotoxic-effect-reply
#15
Jan H M Schellens
No abstract text is available yet for this article.
October 27, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27755245/novel-insights-in-pathophysiology-of-antiblastic-drugs-induced-cardiotoxicity-and-cardioprotection
#16
Martino Deidda, Rosalinda Madonna, Ruggiero Mango, Pasquale Pagliaro, Pier P Bassareo, Lucia Cugusi, Silvio Romano, Maria Penco, Francesco Romeo, Giuseppe Mercuro
Despite advances in supportive and protective therapy for myocardial function, heart failure caused by various clinical conditions, including cardiomyopathy due to antineoplastic therapy, remains a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators have been searching for alternative treatments that can effectively repair the damaged heart and permanently restore its function. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as trastuzumab...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27721532/benefits-of-antihypertensive-medications-for-anthracycline-and-trastuzumab-induced-cardiotoxicity-in-patients-with-breast-cancer-insights-from-recent-clinical-trials
#17
Katarzyna Rygiel
Advances in oncologic therapies have allowed many patients with breast cancer to achieve better outcomes and longer survival. However, this progress has been tempered by cardiotoxicity, associated with anticancer therapies, ranging from subclinical abnormalities to irreversible life-threatening complications, such as congestive heart failure or cardiomyopathy. In particular, exposure to chemotherapy (CHT), including anthracyclines and trastuzumab, can lead to cardiac dysfunction with short- or long-term consequences, among patients with breast cancer...
September 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/27714776/trastuzumab-cardiotoxicity-from-clinical-trials-to-experimental-studies
#18
Balazs T Nemeth, Zoltan V Varga, Wen Jin Wu, Pal Pacher
Epidermal growth factor receptor-2 (HER-2) is overexpressed in 20% to 25% of human breast cancers, which is associated with aggressive tumor growth and poor prognosis. Trastuzumab (Herceptin®) is a humanized monoclonal antibody directed against HER-2, the first highly selective form of therapy targeting HER-2 overexpressing tumors. Although initial trials indicated high efficacy and a favorable safety profile of the drug, the first large, randomized trial prompted a retrospective analysis of cardiac dysfunction in prior trials utilizing trastuzumab...
October 7, 2016: British Journal of Pharmacology
https://www.readbyqxmd.com/read/27699747/-new-hope-for-her2-positive-metastatic-breast-cancer-treatment-trastuzumab-emtansine-t-dm1-from-the-perspective-of-nursing-care
#19
Hsiao-Hsuan Kuo, Wei-Wu Chen
Human epidermal growth factor receptor (HER2)-positive breast cancer is associated with a more aggressive disease and poor prognosis. The development of trastuzumab, a HER2-targeted agent, has changed the paradigm of HER2-positive breast cancer treatment and improved survival rates dramatically. However, metastatic HER2-positive breast cancer patients eventually develop resistance to this treatment regimen eventually. A new anti-HER2 antibody-drug conjugate, Trastuzumab emtansine (T-DM1), has been shown to improve treatment efficacy...
October 2016: Hu Li za Zhi the Journal of Nursing
https://www.readbyqxmd.com/read/27673774/concurrent-trastuzumab-use-with-radiation-therapy-and-the-risk-for-cardiotoxicity
#20
S Yuce Sari, G Yazici, M A Sendur, K Altundag, M Gultekin, F Yildiz, G Ozyigit
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
113309
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"